A simplified version of a treatment pioneered in India to treat limbal stem cell deficiency (LSCD) has demonstrated comparable efficacy to its predecessor but at just 10% of the cost, according to a paper published in the British Journal of Ophthalmology.
- Night-time screen use linked to myopia and poor sleepJune 16, 2021
- DED drops on trackJune 16, 2021
- More patients seeking help for eyestrainJune 16, 2021
more... editor's choice
I have been in hospital. I have been counting my blessings, thankful to be in the hands of people who know what to do when things go wrong. I have been...
Central serous chorioretinopathy (CSCR) is the fourth most common retinal disease¹. But unlike other common retinal diseases, CSCR commonly affects working-age...
Double-Paralympic champion Steve Bate was diagnosed with retinitis pigmentosa (RP) in 2011 and is officially blind, with about 10% of his vision remaining....